The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...

A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom’s continuous glucose monitors. The FDA raised concerns with a design change to a ...

Dexcom is preparing to launch a 15-day version of its G7 continuous glucose monitor, based on data presented Thursday at the Advanced Technologies & Treatments for Diabetes conference. Dexcom ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume ...

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.

Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose ...

In a new study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day ...

SAN DIEGO - DexCom, Inc. (NASDAQ: DXCM), a prominent player in glucose biosensing technology with a market capitalization of $28.75 billion and an "GREAT" financial health rating according to ...

Shares of DexCom Inc. slipped 3.69% to $69.47 Thursday, on what proved to be an all-around poor trading session for the stock ...

SAN DIEGO, CA – DexCom Inc. (NASDAQ:DXCM), a $28.75 billion medical device company specializing in glucose monitoring systems, has announced a change in its independent accounting firm.